Statins: Benefits, Risks, and What to Ask Your Doctor

If your doctor has mentioned statins, you're likely somewhere between two reactions: “I should probably take them” and “I've heard they're dangerous.” Both are understandable, and neither is entirely right.

Statins are the most rigorously studied class of cholesterol-lowering medications in medical history. Decades of large randomized controlled trials have produced an unusually clear evidence base. Understanding what that evidence actually shows — rather than what gets passed around online — is the most useful thing you can do before your next clinical conversation.

How statins work

Statins inhibit HMG-CoA reductase — the rate-limiting step in cholesterol synthesis in the liver. When the liver produces less cholesterol, it compensates by pulling more LDL from the bloodstream through upregulation of LDL receptors. The result: a reduction in circulating LDL cholesterol.

The most commonly prescribed statins are rosuvastatin (Crestor) and atorvastatin (Lipitor) for high-intensity therapy, and simvastatin, pravastatin, and lovastatin at lower intensities. They vary in potency, lipophilicity, and drug interactions.

What the evidence actually shows

The CTT Collaboration — the most important data

The Cholesterol Treatment Trialists (CTT) Collaboration meta-analysis covered over 170,000 participants across 27 randomized statin trials. Key finding: each 39 mg/dL reduction in LDL-C reduces major vascular events — heart attacks, strokes, cardiovascular deaths — by approximately 22%. The relationship is consistent across risk groups, age groups, and baseline LDL levels.

Heart Protection Study (HPS)

The HPS enrolled over 20,000 high-risk adults randomized to simvastatin 40mg or placebo. Simvastatin reduced major vascular events by 24% — including in patients whose LDL was already below 100 mg/dL at enrollment. The implication: cardiovascular risk reduction from statins is not simply a function of how high your LDL was to begin with.

JUPITER — primary prevention evidence

JUPITER enrolled nearly 18,000 adults without cardiovascular disease or high LDL, but with elevated hsCRP. Rosuvastatin 20mg reduced major cardiovascular events by 44% and all-cause mortality by 20% compared to placebo — expanding thinking about who benefits from statins beyond the traditional high-LDL threshold.

Who the 2026 ACC/AHA guideline recommends for statins

Group 1 — Established ASCVD (any age): Prior heart attack, stroke, TIA, or peripheral artery disease. High-intensity statin therapy is recommended.

Group 2 — Very high LDL (ages 20–75): LDL ≥190 mg/dL. High-intensity statin therapy is recommended without additional risk calculation.

Group 3 — Diabetes (ages 40–75): Type 2 diabetes and LDL 70–189 mg/dL. Moderate-intensity statin therapy is recommended.

Group 4 — Primary prevention with elevated risk (ages 40–75): LDL 70–189 mg/dL and estimated 10-year cardiovascular risk ≥7.5%. Statin therapy generally favored at ≥10% 10-year risk.

Statin intensity — what the categories mean

Side effects — separating fact from noise

Statin-associated muscle symptoms (SAMS)

Clinical trials report muscle symptoms in approximately 1–5% of statin users, only modestly higher than placebo. The SAMSON trial (2020) directly tested this: participants took statins and placebo in alternating months without knowing which was which. Finding: 90% of muscle symptoms experienced on statins were also present on placebo. SAMS are real, but significantly amplified by expectation. For genuine SAMS: dose reduction, switching to a less lipophilic statin (pravastatin, fluvastatin), alternate-day dosing, or alternatives such as bempedoic acid.

Diabetes risk

Statins modestly increase new-onset type 2 diabetes risk — approximately 1 additional case per 1,000 patients treated per year. Real, but the cardiovascular events prevented typically outweigh this risk in appropriate patients.

Cognitive effects

Large observational studies and the FDA's own systematic analysis have not found a consistent relationship between statins and dementia or cognitive decline. Some studies suggest potential protective effects. This is not an established side effect.

Questions to ask your doctor

• “What is my estimated 10-year cardiovascular risk, and which tool are you using?”
• “Has my Lp(a) ever been measured? Should it be?”
• “Which statin and dose are you recommending, and why?”
• “What LDL level are we targeting and over what timeline?”
• “If I make significant lifestyle changes for 3 months, when would we reassess?”

If you can’t tolerate statins

Genuine statin intolerance affects an estimated 5–10% of patients. Alternatives include: